U.S. Biotech Industry Analysis

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 30 Aug 2026	US$1.6t	US$173.0b	-US$20,233,807,417.75	16.9x	-77x	9x
Tue, 28 Jul 2026	US$1.4t	US$169.2b	-US$11,770,609,315.86	17x	-117.4x	8.2x
Thu, 25 Jun 2026	US$1.4t	US$170.0b	-US$12,262,674,606.43	16.7x	-110.2x	8x
Sat, 23 May 2026	US$1.3t	US$170.0b	-US$12,290,710,594.65	16.2x	-104.9x	7.6x
Mon, 20 Apr 2026	US$1.3t	US$166.2b	-US$11,948,696,255.58	17.1x	-112.8x	8.1x
Wed, 18 Mar 2026	US$1.3t	US$169.2b	-US$15,453,358,645.17	20x	-84.3x	7.7x
Fri, 13 Feb 2026	US$1.3t	US$165.1b	-US$14,338,026,618.74	22.1x	-90x	7.8x
Sun, 11 Jan 2026	US$1.2t	US$163.5b	-US$15,143,003,806.70	21.1x	-81.5x	7.5x
Tue, 09 Dec 2025	US$1.2t	US$163.6b	-US$16,088,878,351.65	19.1x	-76.8x	7.5x
Thu, 06 Nov 2025	US$1.1t	US$164.1b	-US$16,282,738,859.52	17.5x	-68.8x	6.8x
Sat, 04 Oct 2025	US$1.1t	US$163.5b	-US$18,206,071,363.57	16.7x	-61.8x	6.9x
Mon, 01 Sep 2025	US$1.1t	US$163.5b	-US$18,373,688,758.56	15.4x	-57.4x	6.5x
Wed, 30 Jul 2025	US$978.3b	US$155.2b	-US$22,170,866,971.17	15.8x	-44.1x	6.3x
Fri, 27 Jun 2025	US$928.2b	US$156.0b	-US$23,838,153,787.82	16.8x	-38.9x	6x
Sun, 25 May 2025	US$907.6b	US$155.9b	-US$24,118,382,442.03	15.6x	-37.6x	5.8x
Tue, 22 Apr 2025	US$757.2b	US$119.3b	-US$36,503,635,360.22	19.1x	-20.7x	6.3x
Thu, 20 Mar 2025	US$833.1b	US$118.4b	-US$37,426,956,446.75	20.1x	-22.3x	7x
Sat, 15 Feb 2025	US$843.4b	US$116.6b	-US$36,838,403,221.21	17.6x	-22.9x	7.2x
Mon, 13 Jan 2025	US$947.7b	US$149.4b	-US$26,263,014,335.71	16.6x	-36.1x	6.3x
Wed, 11 Dec 2024	US$1.0t	US$150.0b	-US$26,535,944,620.11	17.9x	-39x	6.9x
Fri, 08 Nov 2024	US$1.1t	US$149.1b	-US$31,021,469,881.25	17x	-35.4x	7.4x
Sun, 06 Oct 2024	US$889.8b	US$113.1b	-US$35,952,253,973.77	22x	-24.8x	7.9x
Tue, 03 Sep 2024	US$909.4b	US$113.1b	-US$35,704,251,292.69	24x	-25.5x	8x
Thu, 01 Aug 2024	US$1.2t	US$165.1b	-US$29,392,630,542.96	30.2x	-41.8x	7.4x
Sat, 29 Jun 2024	US$1.1t	US$164.4b	-US$28,157,592,218.37	28.5x	-40.7x	7x
Mon, 27 May 2024	US$1.1t	US$164.6b	-US$26,653,350,594.72	23.8x	-42.2x	6.8x
Wed, 24 Apr 2024	US$1.1t	US$164.3b	-US$23,439,543,461.97	20.4x	-46.7x	6.7x
Fri, 22 Mar 2024	US$1.2t	US$164.3b	-US$23,898,885,613.21	21.6x	-48.8x	7.1x
Sun, 18 Feb 2024	US$1.2t	US$169.1b	-US$20,519,191,458.58	15.7x	-56.9x	6.9x
Tue, 16 Jan 2024	US$1.4t	US$204.8b	-US$22,498,525,782.00	18.8x	-63.9x	7x
Thu, 14 Dec 2023	US$1.3t	US$204.7b	-US$22,099,611,280.00	19.6x	-59.9x	6.5x
Sat, 11 Nov 2023	US$1.2t	US$204.5b	-US$22,053,784,561.00	18.5x	-54.1x	5.8x
Mon, 09 Oct 2023	US$1.3t	US$207.4b	-US$13,060,168,797.00	17.2x	-96.4x	6.1x
Wed, 06 Sep 2023	US$1.3t	US$207.5b	-US$12,513,012,217.00	17.2x	-102x	6.2x

Current Industry PE

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 9.0x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have deteriorated over the last three years.
Revenues have also declined 5.9% per year.
This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?


US Market	0.25%
Healthcare	-2.16%
Biotech	-2.13%
Biotech	-2.13%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
PURR Hyperliquid Strategies	US$11.61	9.7% +US$872.6m	n/a	PE9x
SMMT Summit Therapeutics	US$13.73	4.3% +US$454.7m	-42.1%	PB17.4x
MDGL Madrigal Pharmaceuticals	US$533.76	3.3% +US$393.2m	21.9%	PS9.6x
INBX Inhibrx Biosciences	US$123.41	19.1% +US$291.1m	337.6%	PE-13.1x
IBRX ImmunityBio	US$8.05	3.3% +US$275.6m	244.0%	PS51.5x

Insmed Incorporated Receives Approval for BRINSUPRI for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

Insmed Incorporated announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older. BRINSUPRI, the first and only MHLW-approved treatment for NCFB, finally gives patients with NCFB and clinicians who treat the disease an option to manage this chronic and progressive disease that can lead to permanent lung damage and lung function decline. With this approval, BRINSUPRI is now approved for use in the U.S., Europe, and Japan. The approval of BRINSUPRI by the MHLW for the treatment of patients living with NCFB is based on results from the Phase 3 ASPEN study, which demonstrated that brensocatib significantly reduced pulmonary exacerbations compared with placebo over the 52-week treatment period and met multiple key secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients treated with brensocatib 25 mg also demonstrated significantly lower lung function decline at week 52, as measured by post bronchodilator forced expiratory volume in 1 second (FEV1), a standard measure of lung function. Brensocatib was generally well tolerated in the study. The most common treatment-emergent adverse events (TEAEs) occurring in at least 5.0% of patients were COVID-19, nasopharyngitis, cough, and headache. Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive, and inflammatory lung disease that causes the airways to become permanently widened due to a cycle of infection, inflammation, lung tissue damage, and mucociliary dysfunction. Patients with NCFB often experience repeated exacerbations, requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, fatigue, and repeated respiratory infections, which can worsen the underlying disease. BRINSUPRI (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in NCFB. The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of patients with non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years and older. BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings. Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene. It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI. The most common adverse reactions =2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions. In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients. The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Hyperliquid Strategies Nets $305.5 Million and Expands HYPE Token Holdings With Equity Raise

Moderna Wins FDA Approval for New COVID-19 Vaccines Targeting 2026-2027 Variant

BioNTech SE And Genentech Terminate Phase 2 Clinical Trial Collaboration For Autogene Cevumeran In Resected Colorectal Cancer

Tezspire Hits Key Phase III Milestone for Eosinophilic Esophagitis Expansion

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

AbbVie Seeks EMA Approval for SKYRIZI Subcutaneous Induction in Crohn’s Disease

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade)

Summit Therapeutics Awaits FDA Decision After Positive Phase III Ivonescimab Results Published

ImmunityBio: ANKTIVA Is Real, The Valuation Isn't

Regeneron: Why I Still See Upside After The Rally

Biogen Unveils Once-Weekly LEQEMBI IQLIK Autoinjector for Early Alzheimer’s in U.S.

Insmed Incorporated Receives Approval for BRINSUPRI for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

VRTX: Kidney And Endocrine Expansion Will Drive Future Stock Upside

New major risk - Revenue size

Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director